...
首页> 外文期刊>Thrombosis Research: An International Journal on Vascular Obstruction, Hemorrhage and Hemostasis >Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models.
【24h】

Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models.

机译:1型纤溶酶原激活剂抑制剂在糖尿病大鼠肾脏中的表达。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

INTRODUCTION: Intrarenal coagulation and fibrinolysis are thought to be involved in the pathogenesis of diabetic nephropathy. However, gene expression of fibrinolytic factors in diabetic nephropathy has not been clearly defined. Therefore we determined the gene expression of fibrinolytic factors in the kidneys of diabetic rats. MATERIALS AND METHODS: As a model of type1 diabetes male Sprague-Dawley rats were used. They were divided into three groups: control, streptozotocin (STZ)-induced diabetic, and insulin-treated diabetic. Otsuka Long-Evans Tokushima Fatty (OLETF) rats were used as a model of type 2 diabetes; and Long-Evans Tokushima Otsuka (LETO) rats, as the control. Renal gene expressions of type-1 plasminogen activator inhibitor (PAI-1), tissue-type PA (tPA), and urokinase-type PA (uPA) were examined by real-time PCR. Localization of PAI-1 mRNA was investigated by in situ hybridization. RESULTS: Renal PAI-1 mRNA levels (versus control) were increased by 60-80% in STZ-induced diabetic rats (10 days or 3 weeks post STZ injection); and insulin treatment reduced this increased expression to the control level. In OLETF rats (38 weeks old), the renal PAI-1 mRNA level was 2.5-fold higher than that in age-matched LETO rats. Both tPA and uPA mRNA levels were significantly lower than those in LETO rats. PAI-1 mRNA was observed in intraglomerular cells and tubular epithelial cells of both models. CONCLUSIONS: Renal PAI-1 gene expression is up-regulated in both type 1 and type 2 diabetic rats, and changes in gene expressions of fibrinolytic factors may play important roles in the development and pathogenesis of diabetic nephropathy.
机译:简介:肾内凝血和纤维蛋白溶解被认为与糖尿病性肾病的发病机制有关。然而,尚未明确定义糖尿病性肾病中纤溶因子的基因表达。因此,我们确定了糖尿病大鼠肾脏中纤溶因子的基因表达。材料与方法:使用Sprague-Dawley雄性大鼠作为1型糖尿病模型。他们分为三组:对照组,链脲佐菌素(STZ)诱导的糖尿病和胰岛素治疗的糖尿病。 Otsuka Long-Evans Tokushima Fatty(OLETF)大鼠被用作2型糖尿病的模型;并以Long-Evans Tokushima Otsuka(LETO)大鼠为对照组。通过实时PCR检测1型纤溶酶原激活物抑制剂(PAI-1),组织型PA(tPA)和尿激酶型PA(uPA)的肾脏基因表达。通过原位杂交研究PAI-1 mRNA的定位。结果:STZ诱导的糖尿病大鼠(注射STZ后10天或3周)肾PAI-1 mRNA水平(相对于对照)升高了60-80%;胰岛素治疗将这种增加的表达降低至对照水平。在OLETF大鼠(38周龄)中,肾脏PAI-1 mRNA水平比年龄相匹配的LETO大鼠高2.5倍。 tPA和uPA mRNA的水平均显着低于LETO大鼠。在两种模型的肾小球内细胞和肾小管上皮细胞中均观察到PAI-1 mRNA。结论:1型和2型糖尿病大鼠肾脏PAI-1基因表达上调,纤溶因子基因表达的改变可能在糖尿病肾病的发生和发展中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号